|
Novartis is committed to providing you with the most updated news and information on Glivec® (imatinib), as well as News on the pharmaceutical industry, haematology, and oncology.
Recent Publications
Hassan I, et al.
Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis.
Annals of Surgical Oncollogy (2008 Jan)
Corless CL, Heinrich MC.
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas.
Annual Review Pathology (2007 Oct 16) [Epub ahead of print]
Picard et al.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Blood (2007 September)
Kantarjian HM et al.
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer (2007 April)
Blay JY et al.
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year:
The French Sarcoma Group-JCO (2007- March)
deLabarthe A et al.
Imatinib combined with induction or consolidation chemotherapy in patients
with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:
results of the GRAAPH-2003 study.
Blood (2007 Feb)
Rousselot P et al.
Imatinib mesylate discontinuation in patients with chronic myelogenous
leukemia in complete molecular remission for more than 2 years.
Blood (2007 Jan)
Brian J. Druker, M.D. et al.
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid
Leukemia
The New England Journal of Medicine (2006 December)
Roy L et al.
Survival advantage from Imatinib compared to the combination Interferon-{alpha}
plus Cytarabine in chronic phase CML: historical comparison between two
phase 3 trials.
Blood (2006 April)
Virtual Exhibit Booth
|
|
|
Haematology News
|
 |
|
Oncology News
|
 |
|